Development of Group B Streptococcal vaccine
NeoStrep is funded by the European Commission FP7 Programme HEALTH
WP5 will be to disseminate findings from the project and to exploit the advances to the benefit of the EU’s pharmaceutical industry, the medical community and the public, ensuring that the results have a route to exploitation.
Make the results from the project available to professionals in the pharmaceutical industry, medical community and to the general public, and to ensure that the results have a route to exploitation both by SMEs and in the vaccine field.
The specific objectives are:
WORK PACKAGE 5